Centers | ||
EU-OPENSCREEN | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Drug Discovery Core |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
The Drug Discovery Core at the University of Utah is an established Service/Recharge center that provides compound collections for screening by University of Utah Faculty. Our mission is to provide customers low-cost and efficient access to chemical... |
Partnerships |
Events |
Jobs |
Yale to Partner with Gilead to Further Cancer ResearchYale and Gilead have entered into a multi-year research collaboration to develop new treatments against cancer. Gilead will provide $40million in funding for research and other infrastructure support for the initial four years. The agreement can... View all Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all The Division of Signal Transduction TherapyA vital asset of the MRC-PPU is the Division of Signal Transduction Therapy (DSTT) which was established in 1998. This division operates as a unique collaboration between scientists in the MRC-PPU (all PIs including Ronald Hay FRS Honorary PI of... View all |
No EVENTS for listing |
No Job Posts |


